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Abstract
Aims: Radiotherapy clinical trials are integral to the development of new treatments to improve the outcomes of patients with cancer. A collaborative study by
the National Cancer Research Institute Clinical and Translational Radiotherapy Research Working Group and the National Institute for Health Research was
carried out to understand better if and why inefficiencies occur in the set-up of radiotherapy trials in the UK.
Materials and methods: Two online surveys collected information on the time taken for UK radiotherapy trials to reach key milestones during set-up and the
research support currently being provided to radiotherapy centres to enable efficient clinical trial set-up. Semi-structured interviews with project managers and
chief investigators identified better ways of working to improve trial set-up in the future.
Results: The timelines for the set-up of 39 UK radiotherapy trials were captured in an online survey showing that the median time from grant approval to trial
opening was 600 days (range 169e1172). There were 38 responses from radiotherapy centres to a survey asking about the current support provided for
radiotherapy research. Most of these centres have more than one type of staff member dedicated to supporting radiotherapy research. The most frequent barrier
to radiotherapy trial set-up identified was lack of physicists’ time and lack of time for clinical oncologists to carry out research activities. Four main themes
around trial set-up were identified from semi-structured interviews: the importance of communication and building relationships, the previous experience of
the chief investigator and clinical trials units, a lack of resources and having the time and personnel required to produce trial documentation and to process trial
approval requests.
Conclusions: This unique, collaborative project has provided up to date information about the current landscape of trial set-up and research support in the UK
and identified several avenues on which to focus future efforts in order to support the excellent radiotherapy trial work carried out across the UK.
 2019 The Authors. Published by Elsevier Ltd on behalf of The Royal College of Radiologists. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).
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Radiotherapy clinical trials are integral to the develop-
ment of new techniques and the testing of new treatments
to improve the outcomes of patients with cancer. There
have been many excellent examples of radiotherapy trials
that have made an impact on clinical practice [1]. However,
it has previously been recognised that there is scope forCollege of Radiologists. This is an open access article under the CC BY license
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in the UK [2]. In order for UK radiotherapy trials to deliver
timely answers to relevant clinical questions and, ulti-
mately, to have the desired impact on clinical practice and
patient care, trial set-up must be efficient and streamlined.
There is growing focus on increasing the impact from
research to ensure the maximum return for funder invest-
ment and for participating patients’ efforts and time [3,4].
We present the results of a project carried out to un-
derstand better if and why inefficiencies occur in the set-up
of UK radiotherapy trials in order to improve this process in
the future. This was a collaborative project undertaken by
two national organisations in the UK: the National Cancer
Research Institute, through its Clinical and Translational
Radiotherapy Research Working Group (CTRad), and the
National Institute for Health Research (NIHR), which sup-
ports the national Radiotherapy Trials Quality Assurance
Group (RTTQA) and also has responsibility to support the
timely set-up and delivery of clinical research studies in
England.
The specific objectives of this project were:
(i) to understand better the barriers to the timely set-
up of radiotherapy trials in the UK;
(ii) to understand better the research support currently
provided to radiotherapy centres to enable clinical
trial set-up and delivery;
(iii) to identify better ways of working to improve set-
up times.
For the purposes of this project, the ‘central site’ refers to
the co-ordinating clinical trials unit (CTU), the ‘recruiting
site’ refers to the sites recruiting patients into a trial and the
‘radiotherapy centre’ refers to a centre that is providing a
radiotherapy service.
Improving clinical trial set-up times is not a UK-only
challenge. Therefore, the lessons learned from the study
will be of interest to both UK and international clinical
trialists.Materials and Methods
Two online surveys collected information about radio-
therapy trial set-up times and the current research support
available at radiotherapy centres in the UK.
Survey 1 was developed by a multidisciplinary team
fromwork stream 3 (WS3) of CTRad and piloted for content
and face validity by one clinical trial co-ordinator. A list of all
UK radiotherapy trials that had required RTTQA approval
between January 2013 and November 2016 was generated
from a RTTQA database and the survey was sent to both the
CTU project managers and chief investigators for each of
these trials. Although not mandatory, since 2010 it is
strongly encouraged and an expectation of CTRad and
funders that all radiotherapy trials in the UK have RTTQA
assessment. Survey 1 collected information on the type of
trial, its radiotherapy complexity and funding source and
asked respondents to report key milestone dates from grantsubmission through to site opening and recruitment.
Radiotherapy complexity assessment was based on the
quality assurance activity as described in key radiotherapy
quality assurance memoranda [5,6]. One open-ended
question asked respondents trial set-up could be
improved in the future. The survey was developed and
distributed using Survey Monkey and analyses were carried
out using Microsoft Excel.
Survey 2 was developed by the NIHR and piloted inter-
nally. There were two main sources of potential survey
participants. First, the survey was sent to all radiotherapy
leads and research delivery managers in the 15 local clinical
research networks (LCRNs) in England. Those recipients
were asked to distribute the survey to clinical oncology
consultants in their local radiotherapy centres. Second, the
RTTQA group sent the survey to all heads of radiotherapy
physics and the associated radiotherapy service managers
in radiotherapy centres in the UK, with the aim of capturing
both the physics and radiographer perspectives. The main
objective of this survey was to gain an understanding of the
radiotherapy research support that exists at radiotherapy
centres in the UK. This survey was developed using Google
forms and analyses were carried out using Microsoft Excel.
Both surveys were online only and were distributed via
embedding an online link into email correspondence.
Descriptive statistics were used to report the results.
To address the third objective for this project, the chief
investigators, and/or their assigned clinical research fellow
or CTU project manager, of eight UK radiotherapy trials
were invited to take part in a semi-structured interview to
discuss the set-up process for their particular trial. The trials
were purposively selected by CTRadWS3 to cover a range of
disease sites, radiotherapy complexity and a mixture of
pharmaceutical and investigator-led trials. Three chief in-
vestigators, one senior research fellow and two project
managers were interviewed. Three interviews were face to
face and two were via telephone (one being a joint inter-
view with a chief investigator and a project manager). In-
terviews were carried out using a topic guide, but the
interviews were informal and participants were able to lead
the conversation to explore issues outside those on the
topic guide if relevant. Thematic analysis [7] using a
framework approach [8] was undertaken by two
researchers.
Figure 1 provides a detailed overview of the methods
used in this study.Results
Survey 1 to Radiotherapy Trial Project Managers to Elucidate
Current Timelines
Responses from the chief investigator or trial co-
ordinator of 35/55 (71%) trials were received. Table 1
shows the trial characteristics and the time taken to reach
key set-up milestones. Figure 2 shows the time to achieve
these milestones based on the complexity of radiotherapy
treatment.
Fig 1. Methods used for study data collection and analysis.
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Current Research Support
Thirty-eight responses to Survey 2 were received overall,
37 from 13 LCRNs and one from Scotland. Four centres
submitted more than one response. Therefore, in total, 34
individual centres of a possible 62 centres responded. The
professional roles for individual respondents were not
captured.
Thirty (76%) respondents indicated that they were
working at radiotherapy centres that recruited to clinical
trials. Thirty-five (92%) indicated they had dedicated
research staff within their radiotherapy departments and
most of these (33/35) had more than one type of staff
member (Table 2). Most staff, regardless of type, were
funded by the NIHR Clinical Research Network or by other
means, such as commercial trial income. The number of
whole time equivalent (wte) staff for each type of post is
shown in Figure 3. Most centres have between 0 and 1 wte
of each staff type in post.
Table 2 outlines the time for key milestones in the pro-
cess of radiotherapy quality assurance. Most respondents
rated the quality and responsiveness of RTTQA as 3e5 out of
5 (28/29 responses; 97%). Of 30 responses, 20 respondents
indicated that they had experienced a delay in trial set-up
due to processes related to their local research and devel-
opment department, but most (25/29 responses; 86%) still
rated the quality and responsiveness of their department
between 3 and 5.Finally, respondents chose factors that they identified as
the biggest barriers to efficient trial set-up in their centre.
Overall, 72 responses were generated (Table 2). There was
also a free text box to allow respondents to describe other
barriers they encountered that were not prespecified in the
survey. These free text responses were analysed themati-
cally alongside the responses to the open questions.
Semi-structured Interviews with Trial Chief Investigators,
Clinical Co-ordinators and Project Managers
Four main themes relevant to trial set-up were derived
from the interviews. The themes are summarised in Figure 4
and direct quotations from the interview transcripts that
are relevant to each theme can be found in Supplementary
Table S1. During the analysis, barriers were identified that
occurred at the central site and the recruiting sites, but the
themes that emerged are cross-cutting, with relevance at
both. This finding indicates that common strategies can be
used to tackle these barriers.
Theme 1: Establishing and Maintaining Relationships and
Pathways of Communication with Key Individuals and
Organisations
This theme encompasses the value of constructive re-
lationships between individuals and the importance of
efficient communication. At the CTU level, establishing
and maintaining strong pathways of communication with
individuals and teams, such as medical physicists,
Table 1
Results of survey 1
Number n ¼ 39 trials (%)
Radiotherapy trial details
Included an investigational
medicinal product
16 (41)
Randomised 33 (85)
Complexity of radiotherapy treatment used in the trial
Minimal 4 (10)
Basic 4 (10)
Moderate 9 (23)
Complex 22 (56)
Treatment Intent
Neoadjuvant 5 (13)
Radical 21 (54)
Adjuvant 8 (21)
Palliative 4 (10)
Mixed 1 (3)
Trial funder
Industry only 1 (3)
Government, including
research council
5 (13)
Charity 31 (79)
Charity and industry 2 (5)
Trial milestones (n ¼ number
of completed responses to
each question)
Median time in
days (range)
Grant approval to ethics
approval (n ¼ 32)
375 (16e1169)
Grant approval to radiotherapy
planning document
finalisation (n ¼ 18)
365 (128e1238)
Grant approval to first
recruiting site opening
(n ¼ 30)
600 (169e1172)
Ethics submission to ethics
approval (n ¼ 37)
72 (16e133)
Ethics approval to first
recruiting site opening
(n ¼ 34)
203 (75e431)
MHRA submission to MHRA
approval (n ¼ 13)
51 (24e374)
Time between planned start
date and actual start date
(n ¼ 28)
175 (7e353)
First site opened to patient
recruited at that site (n ¼ 29)
36 (0e202)
MHRA, Medicines and Healthcare products Regulatory Agency.
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important.
I did not have any links in the medical physics department
to help push this part of the work forward.
There are inevitable delays when dealing with a large cor-
poration .. forming good relationships will make this
easier for future projects.
At recruiting sites, communication between the CTU,
recruiting sites, local research and development teams and
the RTTQA group was an issue. Communication problems
were occasionally attributed to ‘one off’ issues, such as anorganisational change or changing staff members, but more
frequently, there were broader issues of knowing who to
contact, having effective pathways of communication and
agreeing designated roles and responsibilities in advance of
set-up.
. very difficult to get information from the (RTTQA) web-
site and you really need a contact there to get any
information.
No-one had spoken to radiology to ask if they would have
the capacity to report all of the central research scans to
RECIST criteria.
Making use of the skills and resources associated with
organisations such as CTRad and RTTQA and identifying key
individuals, involving them in keymeetings such as those of
the trial management group and keeping pathways of
communication open through active efforts were important
solutions.
There was a physicist and a radiographer on the trial
management group who interacted with the RTTQA team.
Once established, the advice was to foster relationships
formed to build a ‘network’. One example of an extremely
efficient trial set-up was attributed to the work carried out
by the CTU, chief investigator and RTTQA for a previous,
similar trial, in building relationships with sites and
providing support in the set-up and radiotherapy quality
assurance of a novel radiotherapy technique.
Finally, incorporating set timelines into radiotherapy
quality assurance reviews was proposed to improve the
current challenge of effective and timely feedback on
radiotherapy test cases.
Theme 2: Role and Previous Experience of the Chief
Investigator, Clinical Trials Unit and Recruiting Sites
The second theme identified was the role and previous
experience of the chief investigator, the CTU and the
recruiting sites. There was a perceived correlation between
inexperience and a lack of insight into the work required.
The issue of the chief investigator having time within their
normal job plan allocated specifically to trial-related activ-
ities was raised.
It would be difficult to imagine how this workload would
feasibly fit with a chief investigator who does not have
dedicated research time e it would be impossible.
It was suggested that it helps to choose a chief investi-
gator, CTU or recruiting site with experience in the partic-
ular type of trial being run, but when this is not possible,
encouraging experienced individuals and sites to mentor
others can build an environment in which more junior re-
searchers, and sites with less trials experience, can flourish.
In particular, using resources and contacts provided by
CTRad, the use of a deputy chief investigator and a buddy
system between principal investigators at recruiting sites
were mentioned.
CTRad has created a network of people who I could
approach for advice.
Fig 2. Time to reach key milestones based on the complexity of radiotherapy treatment used within the trial.
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gator). This helped communication between the sites/trial
team and RTTQA.
The personal attributes of the chief investigator or their
delegate, such as the ability to be flexible, committed and
willing to dedicate time to the set-up, were recognised as
important and, for the CTU, having robust administrative
abilities is important.
Finally, finding avenues of support for recruiting sites
that are not always reliant on the chief investigator or the
CTU was offered as a possible solution to improve trial set-
up.
Use the RTTQA . This gives another avenue rather than
always having to ask the chief investigator.
Theme 3: Resources: Funding, Staffing and Infrastructure
The third theme addressed the resources required for
efficient trial set-up. This recognised the challenge of
identifying all funding needs at the outset and securing
funding to cover all aspects of the trial no matter how small.
Infrastructure at a national level affected the ability of
central (CTU) sites to proceed with core trial set-up activ-
ities. Once the trial had opened at its first recruiting site,
additional sites that were affected by poor national infra-
structure, such as a lack of specialist radiotherapy equip-
ment, were slower to open. Lack of staffing at recruiting
sites, in particular research nurses, clinical oncologists and
medical physicists, was a common frustration that led to
‘bottlenecks’ in the set-up process.
There was a lack of radiotherapy resources at sites - not
enough linacs at some sites to absorb this trial.
Some consultants were working alone. and did not have
time to do the voluming.
Some interviewees felt that there was ‘no slack in the
system’ and there were ‘no solutions’ to address nationalinfrastructure and staff capacity. Others identified using
national commissioning programmes (Commissioning
through Evaluation) in England or employing additional
staff to do specific tasks in the CTU as possible solutions.
Theme 4: Time and Personnel Needed to Produce Trial
Documentation and to Process Trial Approval Requests
The last theme identified was the work required by all
parties during trial set-up. This included the development
of trial documentation, specifically the trial protocol and
radiotherapy aspects of the protocol or radiotherapy plan-
ning guideline document, as well as pharmacy and radio-
therapy quality assurance documents. If therewere external
parties such as pharmaceutical companies involved, any
iteration of documents, such as the trial protocol, required
approval from all key players.
Each time the protocol for the trial was altered the phar-
maceutical company, as well as all the other parties
involved in the trial, had to review each iteration, which
took time.
The advice given was to start development early, to use
help from national organisations and to avoid using irrele-
vant document templates.
RTTQA acted as a ‘safety net’ as physicists were reviewing
the RT protocol.
I would now be wary of trial protocol templates . make
sure that it is appropriate for the trial that you are
developing.Surveys 1 and 2 Free Text Comments: Qualitative Analysis
Free text responses to open questions in the two online
surveys were coded independently of the interview data,
followed by a comparison between the two different
Table 2
Results of survey 2
Radiotherapy research strategy Number of responses (38 replies to this question)
Radiotherapy centres with a research strategy 20 (53%)
Patient and public involvement Number of responses (20 replies to this question)
Patient and public involvement in the research strategy 12 (60%)
Number of trials open at each radiotherapy centre Number of responses (30 replies to this question)
None 1 (3%)
1e5 trials 11 (37%)
6e10 trials 6 (20%)
11e20 trials 9 (30%)
>20 trials 3 (10%)
Types of radiotherapy research staff* Number of responses (100 responses from 38 respondents)
Radiographer 31 (31%)
Physicist 23 (23%)
Research nurse 16 (16%)
Data manager 17 (17%)
Other (e.g. clinical oncologists, PhD students, clinical fellows, statisticians and clinical scientists) 13 (13%)
Biggest barriers to efficient radiotherapy trial set-up* Number of responses (72 responses from 38 respondents)
Lack of clinical oncologists' time 16 (22%)
Lack of physicists' time 19 (26%)
Lack of radiographer or research nurse support 13 (18%)
Lack of local research and development support 8 (11%)
Other 16 (22%)
Important milestones in the radiotherapy quality assurance process Number of responses
Time for clinical oncologist to volume test case (30 responses)
2 weeks 5 (16%)
1 month 12 (40%)
2 months 9 (30%)
>3 months 4 (13%)
Time from physics department receiving to physicist completing benchmark case (29 responses)
1 week 2 (7%)
2 weeks 3 (10%)
1 month 16 (55%)
2 months 6 (21%)
>3 months 2 (7%)
Time for feedback from central RTTQA after benchmark case submission (29 responses)
1 week 3 (10%)
2 weeks 12 (49%)
1 month 10 (34%)
2 months 4 (14%)
RTTQA, Radiotherapy Trials Quality Assurance Group.
* Respondents could choose more than one answer for this question.
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Fig 3. Whole time equivalent (wte) radiotherapy research staff in UK radiotherapy research centres.
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tent with those developed from the interview data.
In Survey 1, a specific solution proposed to improve
communication between CTUs and RTTQAwas to include all
interested parties (CTU, RTTQA and recruiting sites) into
correspondence to improve transparency around timelines
and review activities. A barrier not mentioned in the in-
terviews was the challenge of dealing with an international
trial group, particularly when organising trial documents.
Adapting radiotherapy guideline documents to be used byFig 4. Themes identified from interview data (CI ¼sites across the UK with different planning systems and
differences of opinion in correct cost attribution of
research-related activity between CTUs and some recruiting
sites were also barriers not picked up in the interviews.
In Survey 2, the ‘other’ barriers to set-up identified by
radiotherapy research staff were analysed. There was a
strong focus on the theme of resources, in particular fund-
ing for all staff and difficulties with staff capacity of data
managers, trial co-ordinators, nurses, clinical oncologists
and medical physicists.Chief Investigator, CTU ¼ Clinical Trial Unit).
Table 3
Strategies to improve UK radiotherapy trial set-up
Strategy for change Already in action or possible future solutions
Establishing and maintaining relationships and pathways of communication with key individuals and organisations
RTTQA group responsiveness Implement turnaround time for RT QA
submissions.
Turnaround times for pre-trial and on-trial case
reviews defined.
All trials allocated a trial-specific generic email
address for multiple user access to ensure back
up for RT QA review.
RTTQA group accessibility Improve website organisation and
functionality.
Website facility being reviewed as part of the
larger RTTQA group IT infrastructure
development.
Role and previous experience of the CI, CTU and recruiting sites
Supporting the CI and CTU Develop RT trial protocol and planning
guideline templates.
RT protocol checklist available through CTRad
to support the writing of the RT aspects of a
protocol.
RTTQA can provide RT planning guideline
templates.
Previous trial documentation available on
request through the appropriate channels to
support the writing of new trial protocol and
guidelines.
Develop a practical guide to setting up a RT
trial to assist less experienced CIs and CTUs
identify work required. This should include
expected timelines with the aim of reducing
the lengthy time between grant approval
and ethical approval.
CTRad WS3 and RTTQA working group
convened to promote closer relationships and
standardise working practices between RTTQA
and all UK CTUs.
There are plans by RTTQA to routinely record
and audit trial set-up times for every trial at
each centre from April 2020. This will provide
transparency, indicate if expected timelines are
realistic and being met, and highlight areas for
ongoing improvement.
Supporting and educating CTU specialist
staff.
CTRad and NCRI Cancer CTU Group RT
workshop to explain RT treatment, delivery and
side-effects to CTU staff working on RT trials.
Improved correspondence and sharing of
information between RTTQA and CTUs.
Include all parties in correspondence where
appropriate but particularly in relation to site
approvals.
Invite key members of the multidisciplinary
team onto the TMG.
Incorporate this suggestion into any guidelines
regarding protocol development group.
Support recruiting centres that have less
experience in setting up and running RT
trials.
Set up buddying of high recruiting centres with
new centres that share the same RT technology
to offer support with planning aspects in the
early stages.
Encourage more junior researchers to get
experience in trial set-up early in their
career.
Create ‘chief clinical co-ordinator’ or ‘associate
CI’ role for junior investigators to work under
the mentorship of the trial CI.
Create similar roles for trainees at recruiting
sites: ‘associate PI’ roles. This is already in
progress for UK surgical trainees.
Lack of dedicated resources (e.g. funding, staffing and infrastructure)
Efficiency of IT infrastructure Better data uploading facilities. RTTQA group addressing data upload and
storage for clinical trials. New platform in pilot
testing phase. Full implementation by 2020.
CRNs/funding Highlight correct cost attributions for RT QA
activity.
In 2010, the Department of Health agreed that
clinical trial RT QA is over and above routine QA,
and therefore should be defined as a NHS
service support cost and funded through local
CRN funding.
Study teams should ensure RT QA activities are
clearly defined in the Schedule of Events and
Cost Attribution Tool (SOECAT) as service
support costs.
(continued on next page)
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Table 3 (continued )
Strategy for change Already in action or possible future solutions
Time and personnel needed to produce trial documentation and process trial approval requests
Reduce RT QA workload Streamline RT QA submissions with previous
QA completed and define timelines for
submissions and review.
Streamlining implemented on an anatomical
site basis.
Funding available for RT QA workshops to
support implementation of new RT techniques
in clinical trials.
CI, chief investigator; CRNs, clinical research network; CTRad, Clinical and Translational Radiotherapy Research Working Group; CTU,
clinical trials unit; IT, information technology; NCRI, National Cancer Research Institute; NHS, National Health Service; PI, principal
investigator; QA, quality assurance; RT, radiotherapy; RTTQA, Radiotherapy Trials Quality Assurance Group; SOECAT, Schedule of Events
and Cost Attribution Tool; TMG, trial management group; WS3, Work Stream 3 (phase III trials and methodology).
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physics support that could be given to centres to support
staffing.
One respondent suggested a national approach of
enhancing funding and there was some cautionary advice
from previous experience.
Savings made by centres taking part in trials (e.g. leading to
less radiotherapy, hypofractionated trials leading to less
costs) should be reinvested to centres/RTTQA to ensure
excellent radiotherapy nationally.
When intensity-modulated radiotherapy was rolled out,
many centres including our own had no help or teaching in
what we were doing. The same will be true of stereotactic
ablative radiotherapy and any other techniques.
Survey 2 also asked respondents to suggest how the
radiotherapy quality assurance and research and develop-
ment processes could improve. There was a resource-
specific suggestion for radiotherapy quality assurance con-
cerning better data uploading facilities for benchmark
cases, but most suggestions centred on communication.
Some responded that the research and development teams
did not understand the processes involved in the set-up for
trials involving radiotherapy, in particular the radiotherapy
quality assurance component and the excess treatment
costs required at sites. With regards to research and
development staffing, there were frustrations around holi-
day cover, dealing with the work required in a timely
manner and giving trial staff proper training to complete
the required paperwork. Finally, delays in drafting and
organising documents, such as Ionising Radiation Medical
Exposure Regulations (IRMER) and finance approvals, were
highlighted.
Discussion
The median set-up time for the sample of radiotherapy
trials included in our study was lengthy at 600 days.
Although this is not felt to be unusual for academic cancer
trials, the set-up of high-quality radiotherapy trials requires
some additional steps that can extend the set-up period.We
used a mixed methods approach to identify the challenges
facing radiotherapy trial set-up and the solutions that have
been used by UK trial teams to make this process moreefficient. The participation in this project from project
managers, radiographers, physicists, clinicians and chief
investigators shows a willingness to engage in research to
find ways of improving the set-up process.
Respondents highlighted their perceptions of the bene-
fits of good-quality and efficiently run radiotherapy trials.
Radiotherapy research should be an essential and manda-
tory aspect of daily work. It is not. It is the best way to
ensure national quality assurance and for teaching new
techniques. All centres should be made to take part, if they
have the right support.
Patients can then be treated close to home, knowing they
are offered the latest trials and treatments.
Encouragingly, there were some examples of trials
opening in less than 1 year from grant approval (an often
applied expectation) and most opened within 6 months of
their planned start date. Approvals from large organisa-
tions, such as the Health Research Authority (HRA) and the
Medicines and Healthcare products Regulatory Agency
(MHRA), were efficient and respondents explained that this
was because the timelines for the processes involving these
organisations were often agreed in advance and were
transparent.
It is clear that there is a significant amount of work
during trial development that is resource intense and not
feasible to complete before funding approval. It should
therefore be expected that there will be considerable time
between funding being awarded and submission for regu-
latory approvals to allow the detailed development of trial
documentation, including protocol development and the
definition of radiotherapy-specific guidelines.
Many respondents reflected that if they had understood
better the main tasks involved in trial set-up, especially in
relation to the radiotherapy component, they could have
pre-empted the workload. There was often a lack of un-
derstanding at the site level, local research and develop-
ment and at the LCRN level about how complex
radiotherapy trials differ in expected local set-up time
compared with clinical trials with investigational medicinal
products alone. Local and national recognition of timelines,
radiotherapy processes and documentation requirements
would streamline progression once funding has been
agreed.
C.R. Hanna et al. / Clinical Oncology 32 (2020) 266e275 275There were several examples of insufficient funding or
staff at central and recruiting sites to complete
radiotherapy-specific tasks. This lack of funding, and real-
istic estimates of the time required to do the tasks, were
often not recognised in research applications, funding
awards or trial development timelines.
The limitations of the project include that there is no
known denominator for Survey 2 to indicate how many
individuals received the survey. For both surveys, there is no
information on the non-responders, which means that the
study is open to response bias. There is a possibility that
those who replied to the surveys had more issues with trial
set-up than the non-responders. A small number of in-
terviews were undertaken, however these interviews
covered trials with a range of radiotherapy complexity and
involved different members of the set-up team. Also,
despite these small numbers, there was concordance be-
tween the survey free text comments and the interviews.
In identifying and addressing these key challenges, it is
hoped that the set-up of UK radiotherapy trials can further
improve. This will help to drive forward trials that answer
key clinical questions for patients and permit the UK clinical
oncology community to build on its strong reputation for
supporting excellent radiotherapy research. Some solutions
to the challenges identified are not easily surmountable and
will require time, better funding and improvements in na-
tional infrastructure and resources. However, to begin the
process, we have proposed a number of pragmatic solutions
that may be relatively straightforward in their imple-
mentation. Table 3 outlines strategies to address the chal-
lenges cited by survey respondents and interviewees,
indicating those already in action plus possible future so-
lutions to improve radiotherapy trial set-up in the UK.Conclusions
Clinical trial set-up times can be lengthy. One of the
biggest barriers to efficient trial set-up at radiotherapy
centres is a lack of dedicated medical physics time at sites
and protected clinical time to carry out trial-specific activ-
ities. We identified key themes regarding the challenges
faced by CTUs and recruiting sites during trial set-up and
have reported examples of solutions adopted to overcome
these barriers. All stakeholders must work together to
support continued delivery of practice-changing radio-
therapy trials in a timely manner. We highlight areas for
development and have provided immediate pragmatic so-
lutions to support timely opening of radiotherapy trials.Conflict of Interest
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